Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study
Author:
Affiliation:
1. Inserm, U848, Villejuif;
2. Institut Gustave Roussy, Villejuif;
3. Université Paris-Sud, Paris; and
4. Service d'Hématologie Clinique, Hôpital Avicenne, Université Paris XIII, Bobigny, France
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/111/4/2170/1220698/zh800408002170.pdf
Reference34 articles.
1. New approaches to molecular cancer therapeutics.;Collins;Nat Chem Biol,2006
2. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.;Toschi;Oncologist,2007
3. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.;Bell;J Clin Oncol,2005
4. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.;Herbst;J Clin Oncol,2002
5. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.;Hidalgo;J Clin Oncol,2001
Cited by 100 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development of a cell adhesion-based prognostic model for multiple myeloma: Insights into chemotherapy response and potential reversal of adhesion effects;Oncology Research;2024
2. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells;Cancer Research;2023-12-14
3. Kinase Inhibitors and Interferons as Other Myeloid Differentiation Inducers in Leukemia Therapy;Acta Haematologica;2021-10-21
4. The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells;Frontiers in Oncology;2021-09-28
5. Pharmacokinetic and Pharmacodynamic Assessment of Hydroxychloroquine in Breast Cancer;Journal of Pharmacology and Experimental Therapeutics;2021-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3